Hepta Bio builds a liquid biopsy-native AI platform that reads epigenetic patterns in cell-free DNA from blood to reveal liver biology. It is starting with non-invasive detection of MASH and is designed for routine clinical care.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Hepta Bio shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Full offering memoranda and risk disclosures provided before any commitment is required.
Review and sign subscription agreement. All documents handled digitally through the platform.
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Nov 2025 | Seed |
At Digestive Disease Week 2026, Hepta said its LiquidTransformer found pre-treatment epigenetic signals that separated GLP-1 responders from non-responders. The company said responders were defined as patients with at least 10% weight loss over one year.
Hepta says its liquid biopsy-native AI reads epigenetic patterns in cell-free DNA from a standard blood draw to reveal liver biology and track molecular change over time. Diagnostics World News reported the platform is optimized to analyze contextual relationships across up to one billion molecular interactions per sample.
Hepta says it is decoding tissue-level biology from blood, starting with metabolic dysfunction-associated steatohepatitis, or MASH, for non-invasive detection in routine care. SeaX Ventures says the company aims to prove blood-based epigenetic biomarkers can replace invasive biopsies and expand across chronic diseases.
Interested in Hepta Bio stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
Request access →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, Hepta Bio is a private company and does not trade on any public stock exchange. Accredited investors can access Hepta Bio shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
Hepta Bio does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in Hepta Bio shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.
Pre-IPO investments carry significant risks. Hepta Bio shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
Hepta Bio builds a liquid biopsy-native AI platform that reads epigenetic patterns in cell-free DNA from blood to reveal liver biology, with blood-detectable GLP-1 response signals as a near-term catalyst. Accredited investors can access Hepta Bio stock through UpMarket.